#AskDrDurie

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Nov
15
What is the status of Empliciti® (elotuzumab), the new immunotherapy?
In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in(...)
Nov
08
How important is the FDA approval of once-weekly dosage of Kyprolis (carfilzomib) for multiple myeloma patients?
In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.
Nov
01
What are myeloma warriors?
In this week’s video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back to the myeloma community. BOTTOM LINE: ​ The Myeloma Warrior Spirit means(...)
Oct
25
How is the IMF’s Black Swan Research Initiative working to find a cure for multiple myeloma?
In this week’s video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiative’s 3 “Cure” trials, which use new treatment protocols. BOTTOM LINE: ​ Using new treatment protocols with MRD-(...)
Oct
17
What are bispecific antibodies?
In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials to treat myeloma. BOTTOM LINE:​ Bispecific antibodies are showing(...)
Oct
11
How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients?
In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF). BOTTOM(...)